论文部分内容阅读
目的观察替吉奥治疗晚期转移性乳腺癌的临床疗效。方法回顾性分析30例晚期转移性乳腺癌患者的临床资料,所有患者均在常规治疗基础上予替吉奥治疗,14d为1疗程。观察、比较2组治疗效果(CA153值、化疗周期及疗效)及不良反应发生情况。结果 30例患者治疗前CA153平均值为(34.89±7.22)U/ml,治疗后为(27.13±4.67)U/ml(P<0.05);患者通过2周期化疗12例,4周期化疗14例,6周期化疗3例,8周期化疗1例;近期疗效:CR 0例、PR 11例、SD 13例、PD 6例,无死亡病例;患者中共出现Ⅰ度~Ⅱ度血小板减少11例、Ⅰ度~Ⅲ度白细胞减少17例、Ⅰ度~Ⅱ度乏力8例、Ⅰ度~Ⅱ度贫血28例、Ⅰ度~Ⅱ度肝功能损伤5例、Ⅰ度~Ⅱ度呕吐恶心16例、Ⅰ度~Ⅱ度腹泻3例。结论替吉奥治疗晚期转移性乳腺癌疗效肯定,能明显提升患者生存质量,延长生命周期。且不良反应少,耐受度好,可用作晚期乳腺癌维持治疗,但其具体用药细则仍待大样本量研究进一步确定。
Objective To observe the clinical effect of treatment of advanced metastatic breast cancer for treatment of Gio. Methods The clinical data of 30 patients with advanced metastatic breast cancer were retrospectively analyzed. All the patients were given Gio treatment on the basis of conventional treatment, and one course of treatment was given on the 14th day. Observed, compared two groups of treatment effect (CA153 value, chemotherapy cycle and efficacy) and adverse reactions. Results The mean of CA153 in 30 patients before treatment was (34.89 ± 7.22) U / ml and (27.13 ± 4.67) U / ml after treatment (P <0.05). The patients were treated with 2 cycles of chemotherapy and 14 cycles of 4 cycles of chemotherapy. 6 cases of chemotherapy in 3 cases, 8 cycles of chemotherapy in 1 case; short-term efficacy: CR 0 cases, PR 11 cases, SD 13 cases, PD 6 cases, no deaths were found in patients with grade Ⅰ ~ Ⅱ thrombocytopenia in 11 cases, Ⅰ degree Grade Ⅲ ~ Ⅱ leucopenia in 17 cases, grade Ⅰ ~ Ⅱ degree of weakness in 8 cases, grade Ⅱ ~ Ⅱ anemia in 28 cases, grade Ⅰ ~ Ⅱ liver injury in 5 cases, grade Ⅰ ~ Ⅱ vomiting nausea in 16 cases, Ⅰ degree Ⅱ Degree of diarrhea in 3 cases. Conclusion Treatment of advanced metastatic breast cancer with Gagio has a positive effect, which can significantly improve the quality of life and prolong the life cycle of patients. And less adverse reactions, tolerance is good, can be used as maintenance treatment of advanced breast cancer, but the specific medication details are still large sample size to be further determined.